Linagliptine Viatris

Linagliptin, the active ingredient in Linagliptine Viatris, is a dipeptidyl peptidase‑4 (DPP‑4) inhibitor presented as an oral tablet for oral use. It is indicated for the treatment of type 2 diabetes mellitus as an adjunct to diet and exercise in adult patients.

GNH USA supplies Linagliptine Viatris as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Linagliptine Viatris is a DPP‑4 inhibitor used in the management of type 2 diabetes mellitus. It helps lower blood glucose levels when combined with lifestyle measures.

- Type 2 diabetes mellitus: improves glycaemic control as an adjunct to diet and exercise. - Monotherapy in type 2 diabetes: provides glucose‑lowering effect when other oral agents are unsuitable. - Combination therapy: can be added to metformin, sulfonylureas or insulin to enhance overall glucose control.

Linagliptine Viatris is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Nasopharyngitis: mild upper respiratory tract infection. - Headache: transient mild to moderate pain. - Upper respiratory infection: cough, sore throat. - Dizziness: occasional light‑headedness. - Gastrointestinal upset: nausea, abdominal discomfort.

Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain requiring medical attention. - Severe allergic reactions: angioedema, rash, or anaphylaxis. - Hepatic injury: elevated liver enzymes or jaundice. - Severe hypoglycaemia: when combined with insulin or sulfonylureas. - Bullous pemphigoid: rare skin blistering disorder.

When prescribing Linagliptine Viatris, clinicians should consider several safety aspects. - Renal impairment: monitor renal function; dose adjustment generally not required but caution advised. - Hepatic impairment: use with caution in patients with liver disease. - Cardiovascular disease: observe for any worsening of heart failure symptoms. - Pregnancy: safety not established; avoid unless benefit outweighs risk. - Breastfeeding: unknown safety; consider alternative therapy. - Store at ambient temperature: keep below 25°C, retain in original packaging, protect from moisture.

Linagliptine Viatris may interact with other medicines; awareness of interaction severity helps guide therapy.

Major Interactions (Avoid): - Concomitant use with other DPP‑4 inhibitors: additive effect, risk of excessive inhibition. - Combination with insulin or sulfonylureas: increased risk of hypoglycaemia. - Strong CYP3A4 inducers (e.g., rifampin): may reduce linagliptin exposure.

Moderate Interactions (Monitor Closely):\n- Diuretics: monitor electrolytes and renal function. - ACE inhibitors or ARBs: watch for hypotension. - NSAIDs: assess renal function when used together. - Anticoagulants: observe for any changes in bleeding risk. - Antihypertensives: monitor blood pressure for additive effects.